Back to resultsPharmacotherapy for Schizophrenic Drug Users - 6
Primary Purpose
Cocaine-Related Disorders, Substance-Related Disorders, Shcizophrenia
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Amantadine
Sponsored by
About this trial
This is an interventional treatment trial for Cocaine-Related Disorders focused on measuring anti psychotic agents
Eligibility Criteria
Please contact site for information.
Sites / Locations
- VA Connecticut Healthcare System
Outcomes
Primary Outcome Measures
Drug use
Retention
Psychological symptoms
Schizophrenic symptoms
Secondary Outcome Measures
Full Information
NCT ID
NCT00000281
First Posted
September 20, 1999
Last Updated
December 13, 2016
Sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA), VA Connecticut Healthcare System
1. Study Identification
Unique Protocol Identification Number
NCT00000281
Brief Title
Pharmacotherapy for Schizophrenic Drug Users - 6
Official Title
Pharmacotherapy for Schizophrenic Drug Users
Study Type
Interventional
2. Study Status
Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
September 1994 (undefined)
Primary Completion Date
August 1999 (Actual)
Study Completion Date
August 1999 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA), VA Connecticut Healthcare System
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate maintenance neuroleptics for Schizophrenic patients who are cocaine abusers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine-Related Disorders, Substance-Related Disorders, Shcizophrenia
Keywords
anti psychotic agents
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Enrollment
0 (false)
8. Arms, Groups, and Interventions
Intervention Type
Behavioral
Intervention Name(s)
Amantadine
Primary Outcome Measure Information:
Title
Drug use
Title
Retention
Title
Psychological symptoms
Title
Schizophrenic symptoms
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Please contact site for information.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas R Kosten, M.D.
Organizational Affiliation
VA Connecticut Healthcare System
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Connecticut Healthcare System
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Pharmacotherapy for Schizophrenic Drug Users - 6
We'll reach out to this number within 24 hrs